Tetra Pharm Technologies develops pharmaceutical drugs targeting the central nervous system and immune system to treat neuropathic pain and mental health disorders. The company focuses on improving patient quality of life through scientifically validated therapies that address the unmet needs in neurological and psychological health.
Funding
$9.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neuropathic pain and mental health disorders present significant challenges, often requiring treatments with limited efficacy and considerable side effects. Current pharmaceutical options may not adequately address the underlying mechanisms of these conditions, leaving many patients with unmet needs.
Solution
Tetra Pharm Technologies develops pharmaceutical drugs targeting the central nervous system and immune system to treat neuropathic pain and mental health disorders. The company focuses on creating scientifically validated therapies that improve patient quality of life by addressing the root causes of neurological and psychological ailments. By leveraging advanced research and development, Tetra Pharm Technologies aims to provide innovative solutions that offer improved efficacy and reduced side effects compared to existing treatments. The company is dedicated to operating as a sustainable business and is committed to making a positive impact on the world around us.
Target Audience
The primary target audience includes individuals suffering from neuropathic pain and mental health disorders, as well as healthcare professionals seeking more effective treatment options.
Features
- Focus on pharmaceutical drugs targeting the central nervous system (CNS)
- Development of therapies for neuropathic pain
- Development of therapies for mental health disorders
- Scientifically validated treatment approaches